文献速递其他结缔组织病

血清I型干扰素评分作为弥漫性皮肤型系统性硬化症疾病活动度生物标志物:一项回顾性队列研究

Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study.
PubMed 文献 · Lancet Rheumatol · 2025-03-31

该回顾性队列研究纳入PRESS incident队列110例和STRIKE prevalent队列72例弥漫性皮肤型系统性硬化症患者及32名健康对照,评估血清I型干扰素评分与疾病活动度及结局的关联。Incident队列中IFN-high患者基线FVC、DLCO和HAQ-DI更差,差异持续至末次随访;Prevalent队列中IFN-high患者12个月肺部结局和5年累积死亡率有更差趋势,但未达统计学显著。

要点

  • Incident队列中IFN-high患者基线预测FVC(72.0% vs 85.3%,p=0.0028)和DLCO(56.8% vs 76.6%,p=0.0008)显著低于IFN-low患者。
  • Prevalent队列中IFN-high患者12个月FVC相对恶化9/23(39%)vs 7/41(17%),p=0.051,未达统计学显著。
  • Prevalent队列5年累积死亡率IFN-high 24.9%(95%CI 14.9-39.7)vs IFN-low 8.6%(3.6-19.9),p=0.052,未达统计学显著。

核心结论

  • 血清IFN评分评估或可识别弥漫性皮肤型系统性硬化症中疾病活动度高、12个月预后和总生存更差的患者。

研究设计与样本

  • 回顾性队列研究,纳入美国PRESS前瞻性登记(incident队列)110例、英国STRIKE观察性队列(prevalent队列)72例成人弥漫性皮肤型系统性硬化症患者及32名健康对照。
  • 采用Luminex xMAP多重检测分析血清CCL2、CCL8、CCL19、CXCL9、CXCL10和CXCL11浓度生成IFN评分。
  • 以六种趋化因子自然对数均值和大于(或处于)健康对照两个标准差以内分类为IFN-high(vs IFN-low)。
  • 主要结局指标为基线及12个月时改良Rodnan皮肤评分、FVC、DLCO和健康评估问卷-残疾指数的最小临床重要差异。

主要发现

  • Incident队列中50/110例(45%)为IFN-high,prevalent队列中27/72例(38%)为IFN-high。
  • Incident队列IFN-high患者基线预测FVC为72.0%(SD 18.9)vs IFN-low 85.3%(18.5),p=0.0028;DLCO为56.8%(SD 21.6)vs 76.6%(25.3),p=0.0008;HAQ-DI中位数1.4(IQR 0.8-2.0)vs 0.8(0.4-1.5),p=0.0033。
  • Incident队列FVC和DLCO差异持续至末次随访(FVC中位随访34个月[IQR 19.8-54.0],DLCO中位随访34个月[IQR 22.5-54.0])。
  • Prevalent队列IFN-high患者中位病程2.2年(IQR 0.7-8.2)vs IFN-low 5.0年(1.9-10.0),p=0.035。
  • Prevalent队列12个月FVC相对恶化5%:IFN-high 9/23例(39%)vs IFN-low 7/41例(17%),p=0.051;5年累积死亡率IFN-high 24.9%(95%CI 14.9-39.7)vs IFN-low 8.6%(3.6-19.9),p=0.052。

临床怎么用

  • 原文结论指出血清IFN评分评估或可识别弥漫性皮肤型系统性硬化症中疾病活动度高、更可能12个月预后和总生存更差的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Type I interferon (IFN) pathway activation has been associated with severe systemic sclerosis. We aimed to examine the association of serum IFN scores with disease activity and outcomes in two cohorts of patients with diffuse cutaneous systemic sclerosis. METHODS: In this retrospective cohort study, we included adult (aged >18 years) patients with diffuse cutaneous systemic sclerosis enrolled in the US Prospective Registry of Early Systemic Sclerosis (PRESS; incident cohort) or in the UK observational cohort (Stratification for Risk of Progression in Scleroderma [STRIKE]; prevalent cohort) registries and healthy controls (volunteers). Sera were analysed by Myriad-Rules Based Medicine's Luminex xMAP Technology Multiplex Assay (Austin, TX, USA), and IFN scores were generated using concentrations of CCL2, CCL8, CCL19, CXCL9, CXCL10, and CXCL11. Patients were classified as IFN-high (vs IFN-low) when mean sum of the natural logarithm of the six chemokines was greater than (or within) two standard deviations of healthy controls. The main outcome measures were the baseline and the minimal clinically important differences for modified Rodnan Skin Score, forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), and Health Assessment Questionnaire-Disability Index at 12 months. A person with lived experience of systemic sclerosis was involved in writing the report. FINDINGS: Patients with diffuse cutaneous systemic sclerosis in the PRESS incident cohort were recruited between April 1, 2012, and Jan 1, 2019, and healthy controls and patients in the STRIKE prevalent cohort were recruited between Dec 1, 2014, and Dec 1, 2018. IFN scores were generated for 110 patients in the incident cohort (mean age 50·2 years [SD 15·0], 76 [69%] women and 34 [31%] men, 87 [79%] White) and 72 patients in the prevalent cohort (mean age 51·7 years [SD 10·9], 50 [69%] women and 22 [31%] men, 64 [89%] White), and 32 healthy controls (mean age 47·0 years [SD 12·4]; 19 [59%] women and 13 [41%] men; 24 [75%] White). 50 (45%) of 110 patients in the incident cohort and 27 (38%) of 72 patients in the prevalent cohort were classified as IFN-high. In the incident cohort, patients classified as IFN-high had worse baseline disease compared with patients classified as IFN-low, as assessed by mean predicted FVC (72·0% [SD 18·9] vs 85·3% [18·5]; p=0·0028), DLCO (56·8% [SD 21·6] vs 76·6% [25·3]; p=0·0008), and median Health Assessment Questionnaire-Disability Index (1·4 [IQR 0·8-2·0] vs 0·8 [0·4-1·5]; p=0·0033). Differences in FVC and DLCO persisted at last follow-up (median 34 months [IQR 19·8- 54·0] for FVC and median 34 months [IQR 22·5- 54·0] for DLCO). In the prevalent cohort, patients classified as IFN-high had a shorter median disease duration (2·2 years [IQR 0·7-8·2] vs 5·0 years [1·9-10·0]; p=0·035) compared to those classified as IFN-low, and worse 12-month lung outcomes independent of baseline FVC or immunosuppression (5% relative worsening of FVC in nine [39%] of 23 patients with IFN-high vs seven [17%] of 41 patients with IFN-low; p=0·051). Moreover, cumulative 5-year mortality was 24·9% (95% CI 14·9-39·7) for IFN-high versus 8·6% (3·6-19·9) for IFN-low (p=0·052). INTERPRETATION: Serum IFN score assessment for patients with diffuse cutaneous systemic sclerosis could identify patients with high disease activity who are more likely to have worse 12-month prognosis and overall survival. FUNDING: National Scleroderma Foundation, National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Rheumatic Disease Research Core Centers, National Institute of Health Research Leeds Biomedical Research Centre, and Kennedy Trust for Rheumatology Research.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Hinchcliff M, Khanna D, De Lorenzis E, et al. Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study. Lancet Rheumatol. 2025. PMID: 40179922. doi:10.1016/S2665-9913(24)00403-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。